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Abstract
Recent evidence has highlighted the role of nuclear receptors Peroxisome Proliferator-Activated Receptor (PPAR)
α and PPARγ in the neuroinflammatory state associated with acute inflammatory and neuropathic pain. Its relevance in 
the control and treatment of pain has been confirmed by the beneficial effects of treatment with Thiazolidinediones and 
fibrates. The aim of this study was to evaluate the expression of PPARα, PPARγ, and Nuclear Factor kappa B (NFκB) 
in the brains of rodent models of inflammatory pain, peripheral neuropathy and peripheral nerve injury, including the 
collagen induced arthritis (CIA), Spinal Nerve Transection (SNT) and Anti-Retroviral (ART) models. Our results reveal 
that PPARγ levels are generally reduced in models of persistent pain, while NFκB expression is upregulated, with no 
major changes in PPARα expression. These alterations seem to be linked with the inflammatory state associated with 
the CIA model, but are present in nerve damage models as well. This was further confirmed in vitro, using neuroblastoma 
cells incubated with pro-inflammatory cytokines, with similar changes in the expression of these transcription factors. 
Therefore, these results point to a common pathway in the aetiologies of these different models contributing to further 
exacerbation of pain symptomatology and suggest that this pathway may serve as a target for the development of 
analgesic drugs.
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Introduction
Despite chronic pain being a widespread health issue, current 
management and treatments for the condition are far from satisfactory 
[1]. There are three key causes for chronic pain: tissue injury leading 
to inflammatory pain; nerve damage causing neuropathic pain; and 
tumour growth eliciting cancer pain [2].
Pain is one of the classic signals of the inflammatory process. 
Inflammatory conditions alone can lead to debilitating and persistent 
pain [3]. Inflammation can also be a consequence of conditions such 
as neuropathic pain, where inflammation is secondary to damage to 
the somatosensory nervous system [4]. Inflammatory mediators, such 
as prostaglandins, nerve growth factor, nitric oxide, cytokines, and 
chemokines are released from injury sites and can activate or modify 
nociceptor activities. This directly elicits various forms of pain, resulting 
in peripheral and central sensitisation and ultimately, a chronic 
pain state [5-7]. In fact, inflammatory reactions increase nociceptor 
responsiveness, allowing low-intensity stimuli access to the nociceptive 
pathway and produce pain [8]. In line with this, a widely used approach 
to treat chronic pain is by non-steroidal anti-inflammatory drugs 
(NSAIDs), which prevent nociceptor sensitization. NSAIDs inhibit 
the synthesis of prostaglandins, hence diminishing peripheral and 
central sensitization. However, it is not fully understood whether the 
inflammatory mediators cause and or maintain neuropathic pain.
Several studies suggest that the transcription factor Nuclear Factor 
kappa B (NFκB) could be involved in pain [9]. A significant increase 
in the percentages of activated NFκB immunoreactive neurons and 
GFAP-positive cells under inflamed conditions was reported in the 
dorsal root ganglia of rats [10].
In addition, recent evidence suggests the involvement of Peroxisome 
proliferator-activated receptors (PPARs) in pain regulation [4,11,12]. 
These nuclear receptors are primarily known for their roles in metabolic 
processes and have garnered recent interest in mediating inflammatory 
responses [13-15]. Pioglitazone, a PPARγ synthetic ligand, has been 
shown to present anti-nociceptive and anti-edematogenic effects to 
various animal models [16]. In animal models of neuropathic pain, 
the endogenous PPARγ agonist, 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2, 
a cyclopentanone prostaglandin), decreased mechanical and cold 
hypersensitivity in a dose-dependent manner [17]. Similar findings 
were reported using rosiglitazone, a synthetic PPARγ agonist [17]. 
The 15d-PGJ2 was also effective in alleviating inflammatory pain [6]. 
In addition, LoVerme et al. [18] investigated the effects of the PPARα 
agonists GW7647 and Palmitoyl Ethanilamide (PEA), and both reduced 
hyperalgesia in acute and inflammatory pain models.
Hence, we hypothesize that alterations in the expression of these 
transcription factors in the CNS may contribute to exacerbate allodynia 
and hyperalgesia. Therefore, it is relevant to investigate whether these 
transcription factors are changed during chronic pain. The aim of 
this study was to investigate whether the expression of NFkB and 
PPAR subtypes, γ and α, is affected by different models of chronic 
pain, including a model of inflammatory and two different models of 
neuropathic pain, a nerve injury model and the Anti-Retroviral (ART) 
model of peripheral neuropathy.
Citation: Birch AM, Cheung J, Oluwadare C, Burton J, Huang W, et al. (2016) Alterations in the Expression of Transcription Factors PPARγ and NFκB 
in the Brain of Models of Chronic Pain. Biochem Pharmacol (Los Angel) 5: 217. doi: 10.4172/2177-0501.1000217
Page 2 of 7
Volume 5 • Issue 4 • 1000217
Biochem Pharmacol (Los Angel), an open access journal
ISSN:2177-0501
Materials and Methods
Materials and antibodies
Antibodies used were PPARγ H-100: sc-7196 (Santa Cruz), PPARα 
P0369 (Sigma), anti-p65 (Cell signalling), β-actin (Abcam). TNFα was 
obtained from Roche. All other reagents were obtained from Sigma and 
Invitrogen.
Ethical standards
All animal experiments conformed to the British Home Office 
Regulations (Animal Scientific Procedures, Act 1986) and International 
Association for the Study of Pain guidelines [19] for the care and use 
of animals. We followed the ARRIVE guidelines for reporting the 
behavioral studies in preparing this report [20].
Animals 
In this study, three different models of pain were investigated: 
Collagen Induced Arthritis (CIA) mice as model of inflammatory 
pain [21,22]; and Spinal Nerve Transection (SNT) and Anti-Retroviral 
Neuropathy (ART) rats as models for neuropathic pain. Animals were 
housed and maintained at a temperature of 21 ± 2ºC. Sample size 
estimation was not conducted, as the group number was according 
to the need of the current study, which is mainly a molecular biology, 
based study. Animals were fed with normal chow food (RM1 pelleted 
form; Special Diet Services, Essex, UK) and tap water ad libitum, and 
allowed to acclimatize in their housing environment for at least 48 h 
after arrival. 
Brain tissue from 11 mice (5 Controls; 6 CIA) was provided by Julia 
Inglis (Kennedy Institute). Adult male DBA/1 mice (Charles River) 
ages 10–12 weeks were used. Mice were immunized by subcutaneous 
injection at the base of the tail with 2 50-μl injections of bovine type II 
collagen (2 mg/mL) in CFA (Becton Dickinson, Twickenham, UK), as 
described previously [22]. Fourteen to 28 days following immunization 
the mice developed arthritis and were sacrificed [22]. The rationale for 
choice of route of administration and drug dose were based on your 
previous publication.
For the ART and the SNT models, male adult Wistar rats (180–200 
g; Charles River, UK) were used. Only rats that developed hind paw 
mechanical hypersensitivity of at least 25% change from the baseline 
were included. The experimenter was blinded to the treatments 
received and had no knowledge of the experimental group to which 
an animal was randomized. The rationale for choice of a brief general 
anesthetic, route of administration, and drug dose were based on your 
previous publication.
The ART model was obtained by injecting the HIV antiretroviral 
drug stavudine (d4T) in Wistar rats (n=4 per group) [23]. After 
2 intravenous injections, i.e. via a tail vein under a brief general 
anaesthesia (1–2% isoflurane [Abbott, UK] in O2 and N2O at a 1:1 
ratio), of d4T (a gift from Pfizer Ltd., UK; 50 mg/kg, 4 days apart), rats 
developed hind paw mechanical hypersensitivity, which plateaued at 
21 days after initial d4T injection, as described previously [23]. Vehicle 
control animals received equivalent volumes of sterile saline using the 
same administration protocol for d4T (n=4). 
For the spinal nerve transection (SNT: 4 controls; 4 treated) Wistar 
rats and their controls were produced at Chelsea & Westminster 
Hospital as described in previous publications [24]. Surgery was 
performed under general isofluorane anaesthesia and aseptic surgical 
conditions. Perioperative analgesia (0.05 ml bupivacaine, AstraZeneca, 
UK) and antibiotic treatment (Enrofloxacin (“Baytril”): 0.2 ml/kg, 
Bayer Ltd, Dublin, Ireland) were injected subcutaneously at the start 
of the spinal nerve transection surgery. A 1-2 cm midline skin incision 
was made level with the iliac crests. The left paraspinal muscles were 
separated from spinous processes of L4 to S2 vertebrae using blunt 
dissection. Using anatomical landmarks, the L6 transverse process was 
identified and a small laminectomy performed, exposing L4 and L5 
spinal nerve roots. The left L5 was tightly ligated (4-0 Mersilk, Ethicon) 
and transected 1-2 mm distal to the ligation. Transection of the L5 
nerve root was confirmed post-mortem in all SNT animals. The wound 
was sutured and animals received intraperitoneal post-operative 
analgesia (20% carprofen (“Rimadyl”), 0.5 ml/kg; Pfizer, UK) 4 h post-
surgery. Naive animals did not undergo any surgical procedure but 
were transported and housed in their cages in the surgical room for an 
equivalent period.
Behavioural testing
For the CIA model, animals were scored for clinical signs of 
inflammation, as follows: 0: Normal; 1: Slight swelling and/or 
erythema; 2: Pronounced edematous swelling; and 3: Joint rigidity. 
Each limb was graded, thus allowing a maximum score of 12 per 
mouse. This experiment was repeated on 3 separate occasions [22]. 
Thermal hyperalgesia was assessed using the Hargreaves plantar 
apparatus (Ugo Basile, Varese, Italy), as described previously [22]. The 
mice were placed in the equipment used to assess hyperalgesia on at 
least 2 occasions prior to pain evaluation, in order to reduce stress-
induced behavioral changes. Thermal hyperalgesia was assessed using 
the Hargreaves plantar apparatus (Ugo Basile, Varese, Italy). Briefly, 
mice were placed in a Perspex box, and an increasing thermal stimulus 
was delivered to the plantar surface of the hind paw. The amount of 
time until lifting of the paw was recorded.
Behavioural data using the hind paw mechanical hyper-sensitivity 
are provided to confirm the validity of the models (Supplementary 
information, Figures S1A-S1B) [25]. Animals were tested in individual 
Plexiglas observation chambers (23 × 18 × 14 cm) by a single observer, 
‘blinded’ to group allocation. The hind paw withdrawal threshold 
(PWT) in response to punctate static mechanical stimulation was 
assessed 14 days post-injury or 18 days following the first d4T injection 
using an electronic ‘von Frey’ device (Somedic AB, Hörby, Sweden). 
The calibrated force transducer (0.5 mm2 diameter tip) was manually 
applied to the mid-plantar surface of both left and right hind paw 
alternately (8-15 g/s) until an active limb withdrawal response was 
observed. The threshold value was calculated as the mean of five 
measurements. Two sessions of habituation (40-50 min each) to the 
testing area were conducted. Then, two baseline values were obtained 
for all rats prior to surgery. Mechanical hypersensitivity was defined as a 
post-operative change in the hind paw withdrawal of at least -30% from 
baseline for the SNT model and -25% from baseline for the ART model.
Brains from all experiments were sub-dissected into frontal cortex, 
midbrain, brainstem, cerebellum, and spinal cord. All tissue was snap-
frozen and kept at -80°C for further analysis.
Cell culture
Mouse neuroblastoma of the N2a cell line were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum and penicillin/streptomycin on a 35 mm 
diameter plates. Cells were grown in a 5% CO2 incubator at 37°C and 
were incubated overnight with TNFα (30 ng ml-1).
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Western blot
Brain regions and cells were homogenized in radio-
immunoprecipitation assay buffer (RIPA; 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, 
pH 7.2) supplemented with Roche Complete protease® inhibitor 
cocktail. Proteins were separated on 10% sodium dodecyl sulphate-
polyacrylamide (SDS-PAGE) gels and transferred to Immobilon-P 
polyvinylidene fluoride (PVDF). Following appropriate blocking, 
membranes were incubated with a primary antibody (all at 1:1000 
dilution) overnight at 4°C and then incubated with secondary 
antibodies. Membranes were developed using ECL™ (GE Amersham, 
UK) reagents and Hyperfilm ECL™ audioradiography film in an 
automated developer (Konica, SRX 101A). The intensity of the bands 
was quantified by densitometry using Image J software (NIH) and 
normalized to β-actin.
Statistical analyses
The sample number was based on biostatistical advice and previous 
experience, indicating that group sizes of 4-5 animals are sufficient 
to detect even subtle changes for protein expression analysis. Data 
analysis was performed with GraphPad Prism version 5.01. Unpaired 
t-tests were used to compare the expression of transcription factors 
and pro-inflammatory mediators in control versus CIA, ART, and SNT 
models. In all cases, p < 0.05 was considered statistically significant. 
Results 
The expression of PPARs and NFκB is altered in animal 
models of chronic pain
To allow better understanding towards the underlying mechanisms 
involved in the generation of chronic pain in the CNS, we investigated 
the potential changes in the expression of transcription factors NFkB 
and PPARs in the brain of CIA, SNT, and ART models of chronic pain. 
Because multiple areas all over brain are involved in pain, including 
those involved in sensory-discriminative, cognitive/affect responses 
and endogenous pain control, from cortex to brainstem, we decided to 
test the expression of transcription factors in frontal cortex, midbrain, 
brainstem and cerebellum.
Western blot analysis for PPARγ in different brain regions revealed 
a general reduction in the levels of these receptors in the frontal 
cortex, brainstem cerebellum of all the pain models (Figures 1A-1D). 
In contrast, we observed the opposite tendency in NFκB levels, with 
marked increases in p65 fragment in most brain regions of SNT model 
of neuropathic pain, and midbrain and brainstem of the CIA and 
ART models (Figure 2). On the other hand, no major changes 
were detected in PPARα expression in brains of the SNT and CIA 
models, although PPARα levels were reduced in certain brain areas 
of the ART model of pain (Figure 3).
 
Figure 1: PPARγ expression in models of chronic pain. A) Representative western blots and quantification of PPARγ expression in the frontal cortex of spinal nerve 
spinal nerve transection (SNT), the anti-retroviral model (ART) associated neuropathy model and the collagen induced arthritis (CIA) models of chronic pain (n=3-5 
per group). B) Representative western blots and quantification of PPARγ expression in in the midbrain of the SNT, the ART associated neuropathy model and the CIA 
models of chronic pain (n=2-5 per group). C) Representative western blots and quantification of PPARγ expression in the cerebellum of the SNT, the ART associated 
neuropathy model and the CIA models of chronic pain  (n=3-5 per group). D) Representative western blots and quantification of of PPARγ expression in the brainstem 
of the SNT, the ART associated neuropathy are represented by *p < 0.05 and **p < 0.01.
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Figure 2: NFκB expression in models of chronic pain. A) Representative western blots and quantification of NFκB expression in the frontal cortex of spinal nerve spinal 
nerve transection (SNT), the ART associated neuropathy model and the collagen induced arthritis (CIA) models of chronic pain (n=3-5 per group). B) Representative 
western blots and quantification of NFκB in the midbrain of the SNT, the ART associated neuropathy model and the CIA models of chronic pain (n=2-5 per group). C) 
Representative western blots and quantification of NFκB expression in the cerebellum of the SNT, the ART associated neuropathy model and the CIA models of chronic 
pain (n=3-5 per group). D) Representative western blots and quantification of NFκB expression in the brainstem of the SNT, the ART associated neuropathy model and 
the CIA models of chronic pain (n = 4-5 per group). Columns represent mean ± SEM. Statistical differences are represented by *p < 0.05 and **p < 0.01.
Effect of pro-inflammatory cytokines on the expression of 
PPARs and NFκB 
In order to confirm whether the changes in PPARs and NFκB 
expression in the animal models were consequence of the inflammatory 
component of the model, we repeated the same measurements in N2a, 
which were treated with either vehicle or with 30 ng ml-1 of TNFα, 
because this cytokine has been found increased in CIA models [26]. 
When treated with TNFα, N2a cells shown a significant decrease in 
PPARα (c.24%, p < 0.05) and PPARγ expression (c.19%, p < 0.05) 
(Figures 4A and 4B respectively). On the other hand, a significant 
increase (c.65%, p < 0.005) in p65 was detected under inflammatory 
conditions (Figure 4C), suggesting that changes in inflammatory 
mediators may affect the transcription of PPARs and NFkB, thus 
explaining the changes detected in animal models of chronic pain.
Discussion
Our results identified substantial changes in the expression of 
PPARγ and NFκB across various brain regions in different models of 
persistent pain, in particular those associated with inflammatory pain, 
such as the CIA model. This was further confirmed in vitro, showing 
that changes in PPARα, PPARγ, and NFκB expression in cultured N2a 
cells under inflammatory conditions suggested that the inflammatory 
component of CIA models were likely to be involved in the changes of 
transcription factors.
So far, there are no publications reporting changes in the expression 
of PPARs in animal models of pain. However, it has been previously 
suggested that PPARs might play a role in modulating thermal and 
pain sensations due to their prominent expression in the thalamus, 
particularly in the posterior part of the ventral medial nucleus, a site 
responsive to pain and cold stress and on spinal cord [27,28]. 
Recent publications have suggested PPARγ as a new target for 
treating chronic pain [17,29]. Treatment with PPARγ ligands, such as 
pioglitazone, in the SNT model indicates that pioglitazone alleviates 
neuropathic pain through the attenuation of the up-regulation in 
proinflammatory cytokines [30]. The effect of pioglitazone in reducing 
pain may be mediated by a decrease in glial activation and through 
neuropathic non-genomic and genomic activity [31]. It has been 
shown that inflammatory cytokines and oxidative stress decrease the 
expression of PPARγ mRNA in adipocytes [32] and thiazolidinediones 
reverse this effect [33]. Similarly, we have previously demonstrated 
that certain combinations of inflammatory cytokines can decrease 
PPARγ gene transcription and PPRE activity in neuronal cells [34], 
and this effect is suppressed by incubation with NSAIDs. In line with 
this, it has been reported that TNFα suppresses PPARγ2 transcription 
by inhibiting the binding of C/EBPδ to the PPARγ2 promoter in 
adipocytes [35]. However, we did not observe changes in the levels 
of pro-inflammatory cytokines in brain areas of the SNT model and 
in the ART model (data do not shown). This result is in agreement 
with previous publications reporting neither peripheral nor central 
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Figure 3: PPARα expression in models of chronic pain. A) Representative western blots and quantification of PPARα expression in the frontal cortex of spinal 
nerve spinal nerve transection (SNT), the ART associated neuropathy model and the collagen induced arthritis (CIA) models of chronic pain (n=3-5 per group). B) 
Representative western blots and quantification of PPARα expression in the midbrain of the SNT, the ART associated neuropathy model and the CIA models of chronic 
pain (n=2-5 per group). C) Representative western blots and quantification of PPARα expression in the Cerebellum (n=3-5 per group). D) Representative western blots 
and quantification of PPARα expression in the brainstem of the SNT, the ART associated neuropathy model and the CIA models of chronic pain (n = 4-5 per group). 
Columns represent mean ± SEM. Statistical differences are represented by *p < 0.05.
 
Figure 4: Effect of inflammation in the levels of PPARγ, PPARα and NFκB. Representative western blots and quantification of PPARα (A), PPARγ (B) and NFκB (C) in 
N2a cells incubated with 30 ng/mL of TNFα (n=3). Columns represent mean ± SEM. Statistical differences are represented by *p < 0.05 and **p < 0.01.
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inflammatory cytokine secretion, or neuronal death, or metabolic 
dysregulation contributing to the development of hyperalgesia in the 
model of stavudine orally-induced hyperalgesia (the ART model) in 
rats [36]; however, results in HIV patients taking this medication seem 
to indicate alterations in the levels of adiponectin, which is modulated 
by TNFα [37]. Interestingly, PPARγ agonists have been involved in the 
regulation of this adipose-specific plasma protein that possesses anti-
atherogenic properties [38]. Performing further analysis including 
other inflammatory mediators such as chemokines in the brain of SNT 
and ART models would be necessary to address this point [39].
Both in vitro and in vivo studies have demonstrated that neuronal 
PPARγ prevents COX-2 increase, which in turn may reduce 
prostaglandin synthesis [40]. Hence, the reduction of PPARγ in 
pain models might contribute towards the loss of control of COX-2 
upregulation, ultimately causing pain. Alternatively, the analgesic 
effect of PPARγ agonists could rely upon endogenous opioid activity 
[6]; PPARγ may modulate the transcription of pain receptors, such as 
opioid receptors, and consequently affect nociception. Interestingly, 
both natural and synthetic PPARγ agonists show rapid effects, within 
5 minutes of injection, suggesting a transcription-independent 
pathway of action [11] and mechanism of action. The anti-allodynia 
effects of PPARγ agonists are PPARγ-dependent, which confirms its 
involvement in pain regulation [17].
Although PPARα synthetic agonists, such as fenofibrates, have 
shown beneficial effects in acute and chronic models of inflammatory 
and neuropathic pain [16,18,41,42], no major changes were observed 
in their expression in the CIA and SNT models of chronic pain in 
the present study. However, in diet-induce obese rats the levels of 
PPARα were found down-regulated in spinal cord, and facilitated 
the susceptibility to peripheral inflammatory challenge by increasing 
inflammatory response, contributing to augmented peripheral 
inflammation and inflammatory hyperalgesia [43]. This is in agreement 
with the reduced levels of PPARα found in the ART model and in cells 
incubated with TNFα. Similar to the PPARγ, it has been hypothesised 
that PPARα agonists decrease pain via a non-transcriptional mediated 
mechanism, most likely regulating the activity of ion channels [4]. 
PPARα has been demonstrated to affect NFkB expression [41], as the 
PPARα agonist Fenofibrate upregulates IκBα expression, leading to the 
repression of the p50 subunit of NFkB and C/EBP [44].
The increased NFκB expression in the models of chronic pain 
observed in the present study is in agreement with existing publications 
that suggest that NFκB is regulated by inflammation and could 
be a mediator of pain [9,45]. In rat models of paw inflammation, 
R-flurbiprofen has both antinociceptive and anti-inflammatory effects 
[46]. Other studies demonstrate that R-flurbiprofen potently inhibits 
NFκB activation and its target genes [45], suggesting the involvement 
of NFκB in both the hyperalgesic and inflammatory component of 
the CIA model. On the other hand, activated p50 would seem to be a 
very interesting target to investigate in pain since p50 knockouts mice 
demonstrated reduced acute and inflammatory nociceptive responses [47]. 
In summary, PPARγ and NFκB seem to be oppositely regulated in 
models of chronic pain. In fact, PPARγ has been shown to be able to 
block NFκB actions by several mechanisms, including I-κBα induction 
[48] or by transcriptional transrepression, also known as squelching, 
receptor mutual antagonism, or cross-coupling, therefore interfering 
with NFκB transcriptional activity [49,50].
Conclusion
In conclusion, the results of this study identify alterations in a 
common signalling pathway in different models of persistent pain 
and suggest that changes in PPARs and NFκB seem to be secondary 
to neuroinflammation, therefore contributing to further exacerbation 
of pain symptomatology. The result of interferences with the PPAR 
signalling pathway that has become evident in pain has far reaching 
consequences that extend beyond the pain scenario, affecting 
other conditions where PPARs have a role, including neurological 
pathologies such as Alzheimers disease [34]. Further research needs to 
be highlighted in these areas, as there is the potential that modification 
of this signalling pathway can ameliorate or even reverse these 
pathologies. 
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